Literature DB >> 31054953

Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Anke C Fender1, Reza Wakili2, Dobromir Dobrev3.   

Abstract

Mechanistic understanding of atrial fibrillation (AF) pathophysiology and the complex bidirectional relationship with thromboembolic risk remains limited. Oral anticoagulation is a mainstay of AF management. An emerging concept is that anticoagulants may themselves have potential pleiotropic disease-modifying effects. We here review the available evidence for hemostasis-independent actions of the oral anticoagulants on electrical and structural remodeling, and the inflammatory component of the vulnerable substrate.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Calcium; Protease-activated receptors; Stroke; Thrombin

Mesh：

Substances：

Year:  2019        PMID： 31054953      PMCID： PMC6987959          DOI： 10.1016/j.phrs.2019.104257

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN： 1043-6618            Impact factor:   7.658


  116 in total

1.  Anticoagulation with warfarin downregulates inflammation.

Authors:  P S Maclean; R C Tait; A Rumley; A D McMahon; G D Lowe
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

2.  Challenges to the translation of basic science findings to atrial fibrillation therapies.

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Future Cardiol       Date:  2016-04-19

Review 3.  Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.

Authors:  Henri M H Spronk; Anne Margreet de Jong; Harry J Crijns; Ulrich Schotten; Isabelle C Van Gelder; Hugo Ten Cate
Journal:  Cardiovasc Res       Date:  2014-01-02       Impact factor: 10.787

4.  Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.

Authors:  Paola Altieri; Maria Bertolotto; Patrizia Fabbi; Elena Sportelli; Manrico Balbi; Francesco Santini; Claudio Brunelli; Marco Canepa; Fabrizio Montecucco; Pietro Ameri
Journal:  Int J Cardiol       Date:  2018-05-24       Impact factor: 4.164

Review 5.  Blood coagulation factor Xa as an emerging drug target.

Authors:  Keren Borensztajn; C Arnold Spek
Journal:  Expert Opin Ther Targets       Date:  2011-01-21       Impact factor: 6.902

6.  Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study.

Authors:  Alvaro Alonso; Weihong Tang; Sunil K Agarwal; Elsayed Z Soliman; Alanna M Chamberlain; Aaron R Folsom
Journal:  Int J Cardiol       Date:  2010-10-20       Impact factor: 4.164

7.  Impact of atrial fibrillation on platelet gene expression.

Authors:  Waldemar E Wysokinski; Alfonso Tafur; Naser Ammash; Samuel J Asirvatham; Yanhong Wu; Izabella Gosk-Bierska; Diane E Grill; Joshua P Slusser; Jozef Mruk; Robert D McBane
Journal:  Eur J Haematol       Date:  2017-04-20       Impact factor: 2.997

8.  Heparin Augmentation Enhances Bioactive Properties of Acellular Extracellular Matrix Scaffold.

Authors:  Daniel S J Park; Holly E M Mewhort; Guoqi Teng; Darrell Belke; Jeannine Turnbull; Daniyil Svystonyuk; David Guzzardi; Sean Kang; Paul W M Fedak
Journal:  Tissue Eng Part A       Date:  2017-08-21       Impact factor: 3.845

9.  Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis.

Authors:  L J Downing; R M Strieter; A M Kadell; C A Wilke; L J Greenfield; T W Wakefield
Journal:  J Vasc Surg       Date:  1998-11       Impact factor: 4.268

10.  Effects of the factor Xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice.

Authors:  Pengfei Zuo; Qianxing Zhou; Zhi Zuo; Xin Wang; Long Chen; Genshan Ma
Journal:  Circ J       Date:  2015-09-03       Impact factor: 2.993
View more
  2 in total

1.  Direct oral anticoagulation and severe obesity - One size fits all?

Authors:  Anke C Fender; Monika Gawalko; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2021-12-06

2.  Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.

Authors:  Francisco Sandro Menezes-Rodrigues; José Gustavo Padrão Tavares; Marcelo Pires de Oliveira; Rafael Guzella de Carvalho; Paolo Ruggero Errante; Murched Omar Taha; Djalma José Fagundes; Afonso Caricati-Neto
Journal:  J Thromb Haemost       Date:  2020-08       Impact factor: 16.036
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.